Skip over navigation
Banner
Directory
Directory Search
Jobs
Job Search Post a Job
Patient
Patient Resources Drug Development
History
Genealogy
Toons & Teasers
Industry
 Directory
 Toons & Teasers
Quick Links
 Directory
 Job Search
 Toons & Teasers
 Advertising
 
Facilities
 

EquipNet Auction: Cyteir & Moment Biosciences Late Model Lab Instruments - June 14-15

Sign Up for University of Washington Online Master of Pharmaceutical Bioengineering

Our newest cartoon illustrates "Milestones in Parkinson's"


Indiana Life Science Industry Directory

EquipNet Auction: Former Cyteir Therapeutics and Moment Biosciences Late Model Lab Instruments with 45 Day Right Of Return - June 14-15,  @ 9 am EST

Banner Advertising

Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and delayed by COVID-19, to be launched in 2023 replacing IndianaLifeScience.com. Regrettably, we are working with reduced staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved directory upon the launch of the new site. We apologize for the inconvenience.

Endocyte, Inc.


Endocyte, Inc.
3000 Kent Avenue
West Lafayette, IN 47906
Endocyte, Inc.
 
Phone: (765) 463-7175
Fax: (765) 463-9271
Year Established:  1996
Ticker: NVS
Exchange: NYSE
Main Contact: Matthew Call, VP, Business Development
 
Other Contacts:  Alison A. Armour, M.B., Ch.B., B.Sc., M.Sc., M.D., MRCP., FRCR, CMO
Iontcho Vlahov Ph.D, VP, Discovery Chemistry
Christopher Leamon, Ph.D., VP, R&D
Philip Low, Ph.D., CSO
Michael T. Andriole, CFO
Mike Sherman, President & CEO
 
Company Description
Endocyte, a Novartis company, is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.


Main Industry Directory

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page
© 1997 - 2023 Info.Resource, Inc. All rights reserved.
Privacy Policy . Cookie Policy . Terms of Use . About . Advertising

IndianaLifeScience.com is owned and published by Info.Resource, Inc.